Continuous manufacturing makes monoclonal antibody production faster, cheaper, and greener, say researchers, who predict that industry adoption of the approach will accelerate in response to ...
Scaling-up production of lentiviral vectors (LV)-based therapies is a persistent challenge for biomanufacturers, and one that threatens their development unless commercial-scale production ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results